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According to the NTM-NET consensus statement, a treatment 
eriod of ≥12 months is a prerequisite condition to evaluate the 
reatment outcome of nontuberculous mycobacterial pulmonary 
isease (PD), whether the outcome is treatment failure or not [1] . 
owever, 12 months appears to be too long, especially for pa- 
ients with Mycobacterium abscessus subsp. abscessus ( M. abscessus ) 
D. This is because (i) M. abscessus PD requires prolonged therapy 
ncluding intravenous (i.v.) antibiotics, (ii) adverse events to the 
arenteral agent frequently develop during treatment and (iii) the 
reatment success rate is only 30–40% even with treatment for ≥12 
onths [2 , 3] . Unnecessary long-term treatment in these patients 
ould be avoided by the presence of a clinical marker that can 
redict the treatment outcome early during the treatment course. 
herefore, this study aimed to investigate whether serial sputum 
onversion status after treatment initiation could be used as an 
arly microbiological predictor to determine 1-year treatment out- 
ome in M. abscessus PD. Table 1 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) an
ological cure of Mycobacterium abscessus pulmonary disease at 1 year on a monthly basi
Months since treatment initiation Sensitivity Spe

























213-7165/© 2021 Published by Elsevier Ltd on behalf of International Society for Antimic
icense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Medical records of patients with M. abscessus PD treated with 
.v. amikacin for ≥8 weeks and i.v. β-lactams for ≥2 weeks at three 
ertiary referral centres in Seoul, South Korea, were retrospectively 
ollected from 2005–2019. Treatment modality was not predefined 
ut was determined by attending physicians at each centre. Pa- 
ients were requested to submit the expectorated sputum sample 
ith at least a 1-month interval after treatment initiation. Culture 
onversion and microbiological cure at 1 year after treatment initi- 
tion was determined according to the NTM-NET consensus state- 
ent [1] . The study protocol was approved by the Institutional Re- 
iew Board of each centre, including the Asan Medical Center. 
A total of 57 patients were included in the analysis after ex- 
luding those whose M. abscessus isolate was resistant to clar- 
thromycin [minimum inhibitory concentration (MIC) ≥8 μg/mL at 
ay 3 of incubation]. The mean patient age was 58.6 years and 
8.4% were female. The mean body mass index (BMI) was 20.3 
g/m 2 . Sputum acid-fast bacillus smear positivity was observed in 
1.9% of patients, and 45.6% of patients showed cavitary lesions. 
he presence of inducible resistance (IR) to clarithromycin was de- 
ected in 73.7% (42/57) of M. abscessus isolates. The median dura- 
ion of i.v. amikacin and β-lactam administration was 26.9 weeks 
nd 8.3 weeks, respectively. Among the oral antibiotics adminis- 
ered, azithromycin was prescribed in 86.0% and clarithromycin in 
4.0%. Overall, the microbiological cure rate was 31.6% (18/57). d concordance ( κ) of sputum culture conversion status in predicting the microbi- 
s according to the presence of inducible resistance (IR) to clarithromycin 
cificity PPV NPV κ
4 0.50 0.76 0.15 
4 0.50 0.81 0.30 
4 0.58 0.87 0.46 
7 0.67 0.90 0.58 
7 0.67 0.90 0.58 
0 0.73 0.90 0.63 
0 0.77 0.97 0.77 
0 0.77 0.97 0.77 
4 0.83 0.97 0.82 
4 0.83 0.97 0.82 
7 0.90 0.94 0.81 
0 1.00 0.73 0.59 
0 1.00 0.80 0.73 
0 1.00 0.89 0.87 
8 0.88 1.00 0.87 
8 0.88 1.00 0.87 
0 1.00 1.00 1.00 
0 1.00 1.00 1.00 
0 1.00 1.00 1.00 
0 1.00 1.00 1.00 
0 1.00 1.00 1.00 
0 1.00 1.00 1.00 
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The relationship between monthly sputum culture conver- 
ion status and the treatment outcome at 1 year was analysed. 
able 1 shows the sensitivity, specificity, positive predictive value 
PPV), negative predictive value (NPV) and concordance of monthly 
putum culture conversion status in predicting microbiological 
ure at 1 year. The predictive power of culture conversion status 
ended to increase in the first 4 months and levelled thereafter. 
The NPV of sputum culture conversion at the fourth month of 
reatment was 90% in patients with isolates with IR. This means 
hat the probability of failure to achieve microbiological cure at 
2 months is 90% if the sputum culture positivity persists during 
he first 4 months from treatment initiation. In addition, its PPV, 
ensitivity, specificity and overall concordance were 67%, 73%, 87% 
nd 58%, respectively. A PPV of 67% at 4-month sputum conver- 
ion means that the likelihood of achievement of microbiological 
ure at 1 year would be 67% if sputum conversion is achieved in 
he fourth month of treatment. 
Moreover, the NPV of sputum culture conversion at the fourth 
onth of treatment was 100% in patients with isolates without IR, 
nd its PPV, sensitivity, specificity and overall concordance were 
8%, 100%, 88% and 87%, respectively. This means that persistent 
putum positivity at 4 months indicates the possibility of failure to 
chieve microbiological cure at 12 months with 100% chance, while 
he chance of microbiological cure can be estimated as 88% if cul- 
ure conversion is observed at 4 months after treatment initiation. 
The findings of the present study are in line with a previous 
tudy revealing that early semiquantitative sputum culture results 
an predict long-term sputum conversion in Mycobacterium avium 
omplex PD [4] . In the study subjects, 4-month conversion sta- 
us appears to be the best predictor among the monthly sputum 
ithin 12 months considering that: (i) the predictive power of the 
putum status after 4 months did not appear to be significantly 
ifferent com pared with that of 4 months; (ii) 4 months is an ade-
uate time for the attending physicians to obtain the results of the 
nitial 3 months of sputum culture results; and (iii) it is the early 
eriod that corresponds to one-third of the 12-month treatment 
eriod. 
Therefore, we suggest that sputum culture conversion status at 
 months after treatment initiation could serve as a microbiologi- 
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